US Pathology Laboratories Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 103.84 Bn

Forecast Year, 2035

USD 229.75 Bn

CAGR, 2026 - 2035

7.42%

Report Coverage

U.S.

US Pathology Laboratories Market Size and Forecast 2026 to 2035

The US pathology laboratories market size was calculated at USD 103.84 billion in 2025 and is predicted to increase from USD 112.33 billion in 2026 to approximately USD 229.75 billion by 2035, expanding at a CAGR of 7.42% from 2026 to 2035. The market is growing due to strategic partnerships between hospitals and laboratory service providers and growing demand for oncology, neurology, autoimmune disease, and women's health testing.

Key Takeaways

• By type, the hospital-based segment held the largest revenue share in 2025.
• By type, the diagnostic chains segment is expected to grow at a notable CAGR during the forecast period.
• By testing services, the clinical tests and general physiological segment held the major market share in 2025.
• By testing services, the esoteric tests segment is expected to grow at the highest CAGR between 2026 and 2035.
• By end-use, the physician referrals segment has contributed the highest revenue share in 2025.
• By end-use, the corporate segment is expected to register the fastest CAGR during the forecast period 2026 to 2035.

Market Overview

The U.S. pathology laboratories market refers to services to perform diagnostic tests on all types of specimens (i.e., tissues, blood, cells) for disease detection, support treatment decisions, and monitor the health of patients. The market includes not only hospital-based pathology departments but also independent labs and specialty diagnostics labs that perform services such as cytopathology, histopathology, and molecular/cytogenetic testing. The market will continue to experience solid growth due to the growing burden of many chronic diseases, such as cancer, cardiovascular disease, and infection.

The demand for accurate laboratory testing is increasing due to the rise in popularity of precision medicine, increased use of both molecular and genomic testing, continued advancements in digital pathology, increased automation in laboratories, and the growing number of people age 65 and older. In addition, the increased costs of health care and an increased focus on early disease detection are increasing the importance of pathology laboratories throughout the U.S. and providing numerous service provider growth opportunities.

How is AI Transforming the U.S. Pathology Laboratories Market?

In the U.S., artificial intelligence (AI) is becoming a significant technological advancement in pathology laboratories and will continue to improve laboratory accuracy and workflow when diagnosing patients. AI-based images will help pathologists detect specific abnormalities in the image faster and provide a more reliable diagnosis than conventional methods. The increasing use of digital pathology platforms, the increasing volume of lab tests, and the need for new processes addressing workforce shortages are driving the adoption of AI technology across all types of laboratory operations.

Machine learning enabled algorithms are also utilized for predictive analytics, quality assurance and control, and data application development. Consequently, as healthcare systems increasingly focus on personalized medicine and targeted treatment approaches, AI will continue to play a vital role in improving pathology service delivery by enhancing laboratory management operations to optimize patient safety, quality, and development and deliver better patient outcomes across the U.S.

U.S. Pathology Laboratories Market Trends

• The U.S. is the world's biggest pathology laboratory industry based on its extremely well-developed health system, extensive utilization of diagnostic tests, and strong reimbursement systems. As the incidence of cancer, infectious diseases, and chronic diseases grows, the demand for pathology services increases.
• Laboratory testing plays a very important role in the delivery of health care in the U.S., where an estimated 14 billion laboratory tests are performed each year, according to the U.S. Centers for Disease Control and Prevention (CDC). These numbers show that pathology labs are vital to physician diagnoses and treatment plans.
• The nation has a very large laboratory network. There are approximately 200,000 CLIA-certified laboratories that perform an excess of 13 billion tests every year, providing the population of the U.S. with extensive access to pathology and diagnostic services.
• Government investment in research and innovation in laboratories continues at a high level. The National Institute of Health (NIH) spends nearly $48 billion annually on medical and biomedical research that accelerates innovative molecular pathology, precision medicine, digital pathology, and AI technology-enabled diagnostic processes.
• As the Centers of Medicare and Medicaid Services (CMS) continue adjusting the Clinical Laboratory Fee Schedule (CLFS), there is an increasing focus on improving the quality and standardization of diagnostic tests. This has prompted laboratories to acquire new, advanced testing technologies, automated processes, and to utilize data in pathology.

Market Report Coverage and Key Metrics

Market Dynamics

Drivers

Increasing Demand for Cancer and Chronic Disease Diagnostic Tests

Increased numbers of people being diagnosed and treated for cancer, infectious diseases, and chronic diseases in the U.S. are resulting in additional biopsy, molecular testing, and tissue analysis procedures performed in pathology laboratories. Pathology laboratories are increasing the volume of tests they can perform, as well as the use of new and improved technologies, to provide faster and more accurate clinical decision support and personalized treatment planning to patients being diagnosed with cancer and chronic diseases.

Restraint

Pathologist and Lab Tech Shortage

A continuing shortage of qualified pathologists, histotechnologists, and lab technicians has created limitations on testing availability and workload pressure. Staffing limitations result in delayed turnaround times, increased operating costs, and challenges in meeting the escalation of complex diagnostic and pathology service demand.

Opportunity

Digital Pathology Expansion and AI-Based Diagnostic Tools

New technology, such as digital pathology platforms and AI tools, will offer unique growth opportunities. They improve workflow, provide remote consultation capability, and provide a higher level of accuracy for diagnostic testing. They also enable large-scale image analysis, which allows labs to meet demands and provide a higher quality of diagnostic service by compensating for workforce shortages.

Market Segmentation Analysis

Type Insights

Which Type Segment Dominated the U.S. Pathology Laboratories Market?

The hospital-based segment registered its dominance over the global market in 2025, as a result of its extensive diagnostic infrastructure, high volume of patients being treated, and connection with both inpatient and outpatient care services. The increased need for accurate diagnosis and precision medicine, the growing proclivity for cancer screenings and chronic disease care, have added to the segment's overall growth.

The diagnostic chain labs segment is expected to witness lucrative growth in the market over the studied period, due to additional laboratory consolidation, expanded geographic reach, and investment into more automation technologies. The rising consumer preference for easy access to laboratory diagnostics and increasing collaboration with healthcare providers will help accelerate segment growth consistently throughout the forecasted time frame.

Testing Service Insights

Why Did the Clinical Tests and General Physiological Segment Lead the U.S. Pathology Laboratories Market?

The clinical tests and general physiological segment led the market in 2025, due to increasing incidence of chronic disease, continued preventative screening, and general health assessment requirements. Many tests are done on a routine basis and for general diagnostics in major healthcare settings (i.e., blood test, metabolic panels, urinalysis, etc.). Therefore, clinical testing will remain an important segment within the health tests industry.

The esoteric tests segment is expected to show the fastest growth over the forecast period, as more advanced molecular diagnostic testing, genetic testing, and specialized biomarker analysis become more prevalent. As there is an increased emphasis on personalized medicine and targeted therapies, the increasing demand for complex pathology testing has also increased. Advancements in genomics and precision diagnostics, coupled with a rise in investigations of cancer and rare diseases, contribute to the segment's growth.

End-Use Insights

How the Physician Referrals Segment Dominated the U.S. Pathology Laboratories Market?

The physician referrals segment dominated the market in 2025 because physicians remain the main source of diagnostic test referrals and laboratory services used by patients. Large volumes of tests are conducted due to frequent office visits, chronic illnesses, and routine health checks. Good relationships between physicians and laboratories help solidify the leadership position of this segment in the marketplace.

The corporate segment is expected to gain the highest market share between 2026 and 2035, due to increasing workplace wellness programs and employer-sponsored health screening programs. Organizations are increasingly focusing on preventive care to increase productivity and lower their long-term health care expenses. In addition, the growth of knowledge regarding workplace health management and early detection of illness is expected to drive demand for pathology laboratory services.

Market Competitive Landscape: Leading Companies and Strategies

The U.S. pathology laboratories market is semi-consolidated, with a limited number of companies competing, both large networks of laboratories and independent laboratories that provide local services in regional markets. Established regulatory and branch rules, as well as advanced diagnostics, have contributed to the moderate entry barriers into this marketplace and stimulated competition focused on delivering quality services.

Key players include Falco Holdings Co Ltd, Healius Ltd, A. P. Moller Maersk A/S Class B, Sonic Healthcare Ltd, OPKO Health Inc, Labcorp Holdings Inc, and Quest Diagnostics Inc, allied together through providers that specialize in pathology. They have developed their routes to success through the wide range of testing they provide, the extensive geographic reach of their services, the advanced technology they have access to, and their strong partnerships with the healthcare community.

The competition within this industry will be heavily influenced by acquisitions, the expansion of laboratory networks, the development of digital pathology tools, and AI-assisted diagnostics through the growing investment in precision medicine. Through the many regulatory requirements associated with this industry, particularly with regard to reimbursement and capital expenditures for the infrastructure, new entrants may find it difficult to compete.

Pathology Laboratories Market Companies

• Unilab
• Falco Holdings
• Centro de Diagnósticos
• BioReference
• Healius Limited
• Kingmed Diagnostics
• Metropolis Healthcare
• Dr. Lal Path Labs
• Sonic Healthcare Limited
• SYNLAB International GmbH
• Spectra Laboratories
• Exact Sciences Laboratories LLC
• Laboratory Corporation of America Holdings
• Eurofins Scientific
• Quest Diagnostics Incorporated

Segments Covered in the Report

By Type

• Diagnostic Chains
• Standalone Labs
• Hospital-Based

By Testing Service

• COVID-19 Tests
• Esoteric Tests
• Imaging & Radiology Tests
• Clinical Tests and General Physiological

By End-Use

• Corporate
• Walk-ins
• Physician Referrals